Drug Trial Radar · NCT04242446
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
505
Actual
Start
Feb 19, 2020
Primary completion
Apr 7, 2022
Study completion Feb 19, 2023
Sponsor
- Lead sponsor
- UCB Biopharma SRLUCB
- Sponsor type
- Industry
- First posted
- Jan 27, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)
Conditions
- Hidradenitis Suppurativa
Interventions
BimekizumabDrug
Subjects will receive bimekizumab at pre-specified time-points.
PlaceboOther
Subjects will receive placebo at pre-specified time-points during the Initial Treatment Period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 16Time frame: Week 16
Locations
88 sites in 15 countries. Site status is shown where the registry gives one.
Hs0003 50140
Birmingham, Alabama
Hs0003 50175
Phoenix, Arizona
Hs0003 50161
Los Angeles, California
Hs0003 50220
San Diego, California
Hs0003 50205
North Miami Beach, Florida
Hs0003 50153
Ormond Beach, Florida
Hs0003 50141
Tampa, Florida
Hs0003 50210
Atlanta, Georgia
Hs0003 50280
Watkinsville, Georgia
Hs0003 50425
Murray, Kentucky
Hs0003 50198
Beverly, Massachusetts
Hs0003 50146
Boston, Massachusetts
Hs0003 50194
Omaha, Nebraska
Hs0003 50208
Las Vegas, Nevada
Hs0003 50137
East Windsor, New Jersey
Hs0003 50235
New York, New York
Hs0003 50151
Chapel Hill, North Carolina
Hs0003 50177
Cincinnati, Ohio
Hs0003 50138
Columbus, Ohio
Hs0003 50204
Tulsa, Oklahoma
Hs0003 50147
Hershey, Pennsylvania
Hs0003 50008
Johnston, Rhode Island
Hs0003 50180
Providence, Rhode Island
Hs0003 50142
Nashville, Tennessee
Hs0003 50201
Arlington, Texas
Hs0003 50166
Dallas, Texas
Hs0003 50149
San Antonio, Texas
Hs0003 50270
Seattle, Washington
Hs0003 30015
Campbelltown, Australia
Hs0003 30016
Carlton, Australia
Hs0003 30011
East Melbourne, Australia
Hs0003 30017
Kogarah, Australia
Hs0003 30012
Woolloongabba, Australia
Hs0003 40004
Brussels, Belgium
Hs0003 40121
Brussels, Belgium
Hs0003 40002
Leuven, Belgium
Hs0003 40060
Liège, Belgium
Hs0003 50233
Barrie, Canada
Hs0003 50190
Richmond Hill, Canada
Hs0003 50192
Saskatoon, Canada
Showing 40 of 88 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.